“For Novartis, the separation of Sandoz would further support our strategy of building a focused innovative medicines company,” Vas Narasimhan, MD, Novartis CEO, said in an Aug. 25 news release. “In addition, both companies would be able to focus on maximizing value creation for their shareholders by prioritizing capital and resource allocation, employing separate capital structure policies, and increasing management focus on their respective business needs.”
Like Novartis, Sandoz will be headquartered in Switzerland.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
